OpenAI Restricts Astra AI Over Cyberattack Risks 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
NEW YORK, March 05, 2018 -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the 30th Annual ROTH Conference on Monday, March 12, 2018 at 9:00 a.m. PT in Orange County, CA.
A live audio webcast of the presentation will be available under “Events & Presentations” in the Investors section of SELLAS’ website at www.sellaslifesciences.com/investors. A replay of the webcast will be available for up to 30 days on SELLAS’ website following the presentation.
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesotheliomia (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
[email protected]
David Moser, JD
SELLAS Life Sciences Group, Inc.
813-864-2571
[email protected]
Source: SELLAS Life Sciences Group, Inc.
